About Precipio
Precipio (NASDAQ:PRPO) operates within the biotechnology sector, offering diagnostic tools and services designed to improve patient care. The company specializes in delivering advanced diagnostics for cancer and other diseases, driven by a commitment to accuracy and speed. Its projects include the development of innovative testing methodologies and proprietary technologies aimed at empowering healthcare professionals with reliable diagnostic data. Precipio's objectives are centered around expanding its diagnostic product portfolio, enhancing its technological capabilities, and establishing strong partnerships within the medical community. Through these efforts, the company strives to contribute meaningfully to the advancement of precision medicine and improve outcomes for patients worldwide.
Snapshot
Operations
Products and/or services of Precipio
- IV-Cell, a media formulation for growing cancer cells to enable precise diagnostic testing.
- HemeScreen, a proprietary assay panel designed to accurately diagnose hematologic malignancies like leukemia and lymphoma.
- ICE COLD-PCR, a technology enhancing the detection of cancer mutations in blood and tissue samples.
- COVID-19 testing services, offering rapid and accurate results for both active infections and antibodies.
- Pathology services, providing expert second opinion diagnoses for complex cancer cases.
- Precipio Diagnostic Services, which combines their portfolio of proprietary cancer diagnostic tests with a customer-centric service infrastructure.
Precipio executive team
- Mr. Ilan DanieliFounder, President, CEO & Director
- Mr. Ahmed Zaki SabetChief Operating Officer
- Dr. Ayman A. Mohamed M.D.Chief Technology Officer
- Mr. Matthew GageChief Financial Officer
- Ms. Miri Chiko-RadomskiChief Legal Counsel & People Officer